Effect Of Sacubitril/valsartan On Heart Function In Patients With Heart Failure Reducedd Ejection Fraction

Objective: This purpose of this study is to investigate the effects of sacubitril/valsartan and benazepril hydrochloride on heart function in patients with heart failure reducedd ejection fraction(HFrEF)after one month of treatment.Methods: We selected 40 patients with heart failure reduced ejection fraction hospitalized in the five cardiovascular wards of our hospital from December 2017 to February 2018.They were randomly divided into benazepril hydrochloride group and sacubitril/valsartan group.Two groups of patients were given conventional anti-heart failure treatment.The control group was treated with benazepril hydrochloride(Lotingxin Beijing Novartis Pharmaceutical Co.,Ltd.)10 mg orally once a day.The test group was switched to sacubitril/valsartan(Novozymes Beijing Novartis Pharmaceutical Co.,Ltd.)50 mg orally twice daily after 36 hours of stopping ACEI or 24 hours after ARB,and the dose was doubled every 2 weeks until the target dose was 200 mg.Oral 2 times a day.Results:After one month of treatment with benazepril hydrochloride,the NT-proBNP levels,E/A,E/e,systolic blood pressure,heart rate,weight,and daily average intake were improved compared with those before treatment.The difference was statistically significant(P 0.05).The NT-proBNP level,6-minute walk test,LA,E/A,E/e,systolic blood pressure,heart rate,weight,and daily average intake of the sacubitril/valsartan group were improved after treatment.The difference was statistically significant(P 0.05).Furthermore,the E/A,E/e,6 minutes walk test,systolic blood pressure,weight,and daily average intake of sacubitril/valsartan group were significantly improved compared with benazepril hydrochloride group(P 0.05).The total effective rate after treatment in both groups was statistically significant(P=0.037).Conclusions: Sacubitril/valsartan improves the endurance of patients with heart failure.It is safe and effective.